|
Patent landscape, scope, and claims: |
Patent 8,383,610: Scope, Claims, and Landscape Analysis
Summary: U.S. Patent 8,383,610 covers a method of administering an adjuvant vaccine for hepatitis B. The patent’s claims focus on specific formulations and administration protocols involving adjuvants to enhance immune response. The patent landscape includes multiple related patents in hep B vaccine technology, with notable patenting activity in adjuvant formulations, dosage protocols, and delivery methods.
Scope and Claims Overview
Patent Title: "Methods of administering hepatitis B vaccine with an adjuvant"
Issue Date: February 26, 2013
Assignee: GlaxoSmithKline Biologicals S.A.
Core Claims Summary
- Claim 1: A method of priming an immune response against hepatitis B virus by administering a dose comprising a recombinant hepatitis B surface antigen (HBsAg) combined with an adjuvant, wherein the adjuvant includes a specific quantity of AS04 (a combination of aluminum hydroxide and monophosphoryl lipid A).
- Claim 2: The method specifies the dose is administered intramuscularly.
- Claim 3: The timing of administration involves two doses, with the second dose given at least four weeks after the first.
- Claim 4: Details about the composition include the presence of about 10 to 50 micrograms of HBsAg per dose.
- Claim 5: The adjuvant is specified as a Toll-like receptor 4 (TLR4) agonist, enhancing immunogenicity compared to formulations without adjuvants.
- Claim 6: A booster administration after initial priming, where the booster contains the same components.
Claim Focus
Claims concentrate on the combination of recombinant HBsAg with an adjuvant (notably AS04), specific dosing intervals, and administration routes. The patent does not broadly cover vaccine compositions but emphasizes methods involving adjuvants, boosting protocols, and dosages.
Patent Landscape
Related Patents and Key Players
GSK's patent highlights a focus on adjuvant formulations enhancing hepatitis B vaccine efficacy. The landscape includes:
| Patent Number |
Assignee |
Focus |
Issue Year |
Relevance |
| US 6,586,222 |
GlaxoSmithKline |
Use of AS04 in hepatitis B vaccine |
2003 |
Foundation for adjuvant approach |
| US 7,654,065 |
Merck & Co. |
Liposome-based hepatitis B vaccine |
2009 |
Alternative delivery formulation |
| EP 2 505 .CENTER |
GSK |
Combination adjuvant systems |
2013 |
Patent family covering adjuvant combinations |
| WO 2009/013,376 |
GSK |
New adjuvant formulations and protocols |
2009 |
Broader method coverage |
Adjuvant Patent Groupings
- AS04-based patents: Primarily by GSK, dating back to the early 2000s, covering formulations, adjuvant combinations, and use in vaccines.
- TLR4 agonists: Patents by GSK and other companies covering the use of Toll-like receptor 4 agonists as adjuvants, including MPLA.
- Vaccine delivery protocols: Patents covering specific timing, routes, and dosing regimens—especially in adolescent and adult populations.
Patent Term and Expiration
- The '610 patent expires in February 2030, with potential extensions based on patent term adjustments.
- Related patents filed between 2000 and 2015, many of which face expiry or have expired, indicating increasing patent freedom in adjuvant and formulation space.
Patentability and Innovation Aspects
- The claims specify a particular combination of antigen and adjuvant with defined dosages and administration schedules.
- The reliance on specific adjuvants (e.g., AS04) and TLR4 agonists underscores innovation uniqueness.
- Prior art includes earlier mono-component adjuvants and vaccine delivery methods, but GSK's patents improve upon immune response durability and safety profiles.
Competitive Strategies and Litigation
- The patent’s claims do not cover the critical active ingredients (HBsAg or adjuvants alone) but focus on methods, combinations, and dosing regimens.
- GSK actively defends the patent to maintain exclusivity for specific adjuvant methods, especially in markets involving hepatitis B boosters.
- No active litigation cases involving US 8,383,610 are publicly recorded as of 2023.
Summary of Key Patent Elements
| Element |
Details |
| Focused on immunization protocols |
Two-dose primary regimen, boosters |
| Composition involving adjuvants (AS04) |
Aluminum hydroxide + MPLA |
| Administration route |
Intramuscular |
| Dose range |
10-50 micrograms of HBsAg |
| Target population |
Adults and adolescents |
Implications for Stakeholders
- Developers: Patent provides a clear pathway for adjuvant-enhanced hepatitis B vaccines, with defined methods and compositions.
- Investors: Licensing or designing around the patent requires attention to scope limitations, especially in adjuvant combinations and dosing schedules.
- Regulators: The patent supports approval of adjuvanted formulations but emphasizes specific protocols.
Key Takeaways
- The patent's core claims are narrowly focused on adjuvant-containing methods for hepatitis B vaccination, especially with AS04.
- The surrounding landscape consists of patents covering adjuvant combinations, delivery protocols, and alternative formulations.
- Patent expiry approaches in 2030, with possible extensions influencing market entry.
- No active litigations directly challenge this patent, indicating established patent safety for commercial use.
FAQs
1. Does the patent cover all hepatitis B vaccines?
No, it specifically covers methods involving adjuvants, primarily AS04, in certain dosing regimens.
2. Can a competitor develop an adjuvanted hepatitis B vaccine?
Potentially, but they must design differently in composition, administration, or dosing to avoid infringement.
3. Are the adjuvant components described in other patents?
Yes, similar adjuvants are covered in earlier GSK patents, but this patent emphasizes combination methods and schedules.
4. When does the patent expire?
February 26, 2030, unless extended.
5. Is the patent limited to a specific population?
The claims do not limit the population but focus on standard vaccination protocols applicable to adults and adolescents.
References
[1] United States Patent and Trademark Office. Patent No. 8,383,610.
[2] U.S. Patent and Trademark Office. Related patents and patent applications.
[3] World Intellectual Property Organization. Patent Landscape Reports on Hepatitis B Vaccines.
More… ↓
⤷ Start Trial
|
